Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Journal of clinical oncology

Results: 1-25/712

Authors: Fallowfield, L Fleissig, A Edwards, R West, A Powles, TJ Howell, A Cuzick, J
Citation: L. Fallowfield et al., Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials, J CL ONCOL, 19(7), 2000, pp. 1885-1892

Authors: Gore, M Huinink, WT Carmichael, J Gordon, A Davidson, N Coleman, R Spaczynski, M Heron, JF Bolis, G Malmstrom, H Malfetano, J Scarabelli, C Vennin, P Ross, G Fields, SZ
Citation: M. Gore et al., Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovariancancer, J CL ONCOL, 19(7), 2000, pp. 1893-1900

Authors: Markman, M Kennedy, A Webster, K Peterson, G Kulp, B Belinson, J
Citation: M. Markman et al., Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and Fallopian tube and primary carcinoma of the peritoneum, J CL ONCOL, 19(7), 2000, pp. 1901-1905

Authors: Schwartz, SM Daling, JR Shera, KA Madeleine, MM McKnight, B Galloway, DA Porter, PL McDougall, JK
Citation: Sm. Schwartz et al., Human papillomavirus and prognosis of invasive cervical cancer: A population-based study, J CL ONCOL, 19(7), 2000, pp. 1906-1915

Authors: Gaynon, PS Bostrom, BC Hutchinson, RJ Lange, BJ Nachman, JB Steinherz, PG Sensel, MG Lee, MK Stram, DO Sather, HN
Citation: Ps. Gaynon et al., Duration of hospitalization as a measure of cost on childrens cancer groupacute lymphoblastic leukemia studies, J CL ONCOL, 19(7), 2000, pp. 1916-1925

Authors: Green, DM Grigoriev, YA Nan, B Takashima, JR Norkool, PA D'Angio, GJ Breslow, NE
Citation: Dm. Green et al., Congestive heart failure after treatment for Wilms' tumor: A report from the National Wilms' Tumor Study Group, J CL ONCOL, 19(7), 2000, pp. 1926-1934

Authors: Millot, F Suciu, S Philippe, N Benoit, Y Mazingue, F Uyttebroeck, A Lutz, P Mechinaud, F Robert, A Boutard, P Marguerite, G Ferster, A Plouvier, E Rialland, X Behard, C Plantaz, D Dresse, MF Philippet, P Norton, L Thyss, A Dastugue, N Waterkeyn, C Vilmer, E Otten, J
Citation: F. Millot et al., Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organizationfor Research and Treatment of Cancer 58881 Randomized Phase III Trial, J CL ONCOL, 19(7), 2000, pp. 1935-1942

Authors: Gobel, U Schneider, DT Calaminus, G Jurgens, H Spaar, HJ Sternschulte, W Waag, K Harms, D
Citation: U. Gobel et al., Multimodal treatment of malignant sacrococcygeal germ cell tumors: A prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89, J CL ONCOL, 19(7), 2000, pp. 1943-1950

Authors: Schneider, DT Wessalowski, R Calaminus, G Pape, H Bamberg, M Engert, J Waag, K Gadner, H Gobel, U
Citation: Dt. Schneider et al., Treatment of recurrent malignant sacrococcygeal germ cell tumors: Analysisof 22 patients registered in the German protocols MAKEI 83/86, 89, and 96, J CL ONCOL, 19(7), 2000, pp. 1951-1960

Authors: Kies, MS Haraf, DJ Rosen, F Stenson, K List, M Brockstein, B Chung, T Mittal, BB Pelzer, H Portugal, L Rademaker, A Weichselbaum, R Vokes, EE
Citation: Ms. Kies et al., Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer, J CL ONCOL, 19(7), 2000, pp. 1961-1969

Authors: Hosch, SB Stoecklein, NH Pichlmeier, U Rehders, A Scheunemann, P Niendorf, P Knoefel, WT Izbicki, JR
Citation: Sb. Hosch et al., Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance, J CL ONCOL, 19(7), 2000, pp. 1970-1975

Authors: Marijnen, CAM Nagtegaal, ID Kranenbarg, EK Hermans, J van de Velde, CJH Leer, JWH van Krieken, JHJM
Citation: Cam. Marijnen et al., No downstaging after short-term preoperative radiotherapy in rectal cancerpatients, J CL ONCOL, 19(7), 2000, pp. 1976-1984

Authors: Schwartz, GK Ilson, D Saltz, L O'Reilly, E Tong, W Maslak, P Werner, J Perkins, P Stoltz, M Kelsen, D
Citation: Gk. Schwartz et al., Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma, J CL ONCOL, 19(7), 2000, pp. 1985-1992

Authors: Vicini, FA Baglan, KL Kestin, LL Mitchell, C Chen, PY Frazier, RC Edmundson, G Goldstein, NS Benitez, P Huang, RR Martinez, A
Citation: Fa. Vicini et al., Accelerated treatment of breast cancer, J CL ONCOL, 19(7), 2000, pp. 1993-2001

Authors: Munster, PN Buzdar, A Dhingra, K Enas, N Ni, L Major, M Melemed, A Seidman, A Booser, D Theriault, R Norton, L Hudis, C
Citation: Pn. Munster et al., Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer, J CL ONCOL, 19(7), 2000, pp. 2002-2009

Authors: Malmstrom, P Bendahl, PO Boiesen, P Brunner, N Idvall, I Ferno, M
Citation: P. Malmstrom et al., S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic gradein a prospective study of premenopausal lymph node-negative breast cancer, J CL ONCOL, 19(7), 2000, pp. 2010-2019

Authors: Rabbani, F Sheinfeld, J Farivar-Mohseni, H Leon, A Rentzepis, MJ Reuter, VE Herr, HW McCaffrey, JA Motzer, RJ Bajorin, DF Bosl, GJ
Citation: F. Rabbani et al., Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse, J CL ONCOL, 19(7), 2000, pp. 2020-2025

Authors: Rueffer, U Josting, A Franklin, J May, M Sieber, M Breuer, K Engert, A Diehl, V
Citation: U. Rueffer et al., Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: Incidence, treatment, and prognosis, J CL ONCOL, 19(7), 2000, pp. 2026-2032

Authors: Chim, CS Liang, R Tam, CYY Kwong, YL
Citation: Cs. Chim et al., Methylation of p15 and p16 genes in acute promyelocytic leukemia: Potential diagnostic and prognostic significance, J CL ONCOL, 19(7), 2000, pp. 2033-2040

Authors: Morgner, A Miehlke, S Fischbach, W Schmitt, W Muller-Hermelink, H Greiner, A Thiede, C Schetelig, J Neubauer, A Stolte, M Ehninger, G Bayerdorffer, E
Citation: A. Morgner et al., Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection, J CL ONCOL, 19(7), 2000, pp. 2041-2048

Authors: Parker, PA Baile, WF de Moor, C Lenzi, R Kudelka, AP Cohen, L
Citation: Pa. Parker et al., Breaking bad news about cancer: Patients' preferences for communication, J CL ONCOL, 19(7), 2000, pp. 2049-2056

Authors: Casarett, D Abrahm, JL
Citation: D. Casarett et Jl. Abrahm, Patients with cancer referred to hospice versus a bridge program: Patient characteristics, needs for care, and survival, J CL ONCOL, 19(7), 2000, pp. 2057-2063

Authors: Velikova, G Wright, P Smith, AB Stark, D Perren, T Brown, J Selby, P
Citation: G. Velikova et al., Self-reported quality of life of individual cancer patients: Concordance of results with disease course and medical records, J CL ONCOL, 19(7), 2000, pp. 2064-2073

Authors: Carde, P Timmerman, R Mehta, MP Koprowski, CD Ford, J Tishler, RB Miles, D Miller, RA Renschler, MF
Citation: P. Carde et al., Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases, J CL ONCOL, 19(7), 2000, pp. 2074-2083

Authors: Ewesuedo, RB Iyer, L Das, S Koenig, A Mani, S Vogelzang, NJ Schilsky, RL Brenckman, W Ratain, MJ
Citation: Rb. Ewesuedo et al., Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer, J CL ONCOL, 19(7), 2000, pp. 2084-2090
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>